339 related articles for article (PubMed ID: 15592807)
21. Apomorphine-induced penile erections in Parkinson's disease.
O'Sullivan JD; Hughes AJ
Mov Disord; 1998 May; 13(3):536-9. PubMed ID: 9613749
[TBL] [Abstract][Full Text] [Related]
22. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease.
Stocchi F; Berardelli A; Vacca L; Barbato L; Monge A; Nordera G; Ruggieri S
Clin Neuropharmacol; 2003; 26(3):151-5. PubMed ID: 12782918
[TBL] [Abstract][Full Text] [Related]
23. Role of apomorphine in the treatment of Parkinson's disease.
Boyle A; Ondo W
CNS Drugs; 2015 Feb; 29(2):83-9. PubMed ID: 25676564
[TBL] [Abstract][Full Text] [Related]
24. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
Koller W; Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
[TBL] [Abstract][Full Text] [Related]
25. Apomorphine: North American clinical experience.
Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S18-21. PubMed ID: 15037667
[TBL] [Abstract][Full Text] [Related]
26. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
27. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
[TBL] [Abstract][Full Text] [Related]
28. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
Trenkwalder C; Chaudhuri KR; García Ruiz PJ; LeWitt P; Katzenschlager R; Sixel-Döring F; Henriksen T; Sesar Á; Poewe W; ; Baker M; Ceballos-Baumann A; Deuschl G; Drapier S; Ebersbach G; Evans A; Fernandez H; Isaacson S; van Laar T; Lees A; Lewis S; Martínez Castrillo JC; Martinez-Martin P; Odin P; O'Sullivan J; Tagaris G; Wenzel K
Parkinsonism Relat Disord; 2015 Sep; 21(9):1023-30. PubMed ID: 26189414
[TBL] [Abstract][Full Text] [Related]
29. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
[TBL] [Abstract][Full Text] [Related]
30. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
[TBL] [Abstract][Full Text] [Related]
31. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
Carbone F; Djamshidian A; Seppi K; Poewe W
CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
[TBL] [Abstract][Full Text] [Related]
33. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
Schelosky L; Poewe W
Acta Neurol Scand Suppl; 1993; 146():46-9. PubMed ID: 8101415
[TBL] [Abstract][Full Text] [Related]
34. Rapid treatment of "wearing off" in Parkinson's disease.
Swope DM
Neurology; 2004 Mar; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
[TBL] [Abstract][Full Text] [Related]
35. Apomorphine (Apokyn) for advanced Parkinson's Disease.
Med Lett Drugs Ther; 2005 Jan; 47(1200):7-8. PubMed ID: 15647705
[TBL] [Abstract][Full Text] [Related]
36. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
LeWitt PA; Ondo WG; Van Lunen B; Bottini PB
Clin Neuropharmacol; 2009; 32(2):89-93. PubMed ID: 18978491
[TBL] [Abstract][Full Text] [Related]
37. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
Maggio R; Barbier P; Corsini GU
J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
[TBL] [Abstract][Full Text] [Related]
38. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
39. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
40. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
Bibbiani F; Costantini LC; Patel R; Chase TN
Exp Neurol; 2005 Mar; 192(1):73-8. PubMed ID: 15698620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]